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Congenital mesoblastic nephroma (CMN) is a rare renal tumor of infancy. Here, we present a case of CMN
presenting in a 29 week premature male in a twin gestation. An abdominal mass had been noted on
prenatal ultrasound. He was initially treated with right radical nephrectomy. Pathology was consistent
with cellular type CMN. Three months postoperatively, the patient developed pulmonary metastasis and
underwent wedge resection of the right lung lesion. He subsequently underwent adjuvant chemo-
therapy, to which he has responded well. We discuss the presentation and management of patients with
CMN and address the indications for postoperative chemotherapy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Congenital mesoblastic nephroma (CMN) is a rare renal tumor,
accounting for up to 4% of all pediatric renal tumors; however, it is
the most common renal neoplasm in infants up to three months of
age [1]. Diagnosis is frequently made in utero as a mass or poly-
hydramnios identiﬁed on prenatal ultrasound. It is generally
considered a benign tumor however there are reports of recurrent
and metastatic disease [2e6]. Here we present a case of a prema-
ture infant from a twin gestation that was diagnosed with CMN and
later developed distant metastatic disease.2. Case report
A 31 year-old G2P1 female, 19 weeks gestation with twin males
following in vitro fertilization, presented with premature rupture of
membranes for Twin B. This was managed with bed rest therapy. At
27 weeks gestational age, prenatal ultrasound demonstrated an
abdominal mass in Twin A. Two weeks later, the mother developed
preterm labor, leading to an emergent Caesarean section. Twin A
was born at 1360 g with normal amniotic ﬂuid. Twin B was born atate University of New York -
n, NY, 11203, USA.
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Inc. This is an open access article u1000 g with oligohydramnios and expired several hours after de-
livery due to fulminant cardiopulmonary collapse secondary to
pulmonary hypoplasia.
Twin A was admitted to the neonatal intensive care unit. The
infant was noted to have a large palpable abdominal mass on
physical exam. An abdominal ultrasound demonstrated a mass in
the right upper quadrant with punctate calciﬁcations; a computed
tomography (CT) scan showed a 8  5.6  6.9 cm mass with no
evidence of a right kidney or adrenal gland, and the small calciﬁ-
cations from the ultrasound were not seen (Fig. 1). Following
medical stabilization in the neonatal intensive care unit he was
taken to the operating room on day of life 12.
Exploratory laparotomy was performed via a transverse
abdominal incision. A 7.5  5.5  5 cm mass was noted from the
right kidney (Fig. 2). Upon inspection of the abdomen there was no
evidence of metastatic disease. A right radical nephrectomy was
performed with no evidence of any gross residual tumor. The post-
operative course was complicated by respiratory insufﬁciency and
required mechanical ventilation for three weeks following surgery.
Pathology results were consistent with CMN, cellular subtype.
The tumor was noted to inﬁltrate the adjacent renal parenchyma
with positive medial, peri-hilar margins, making this a Stage III
tumor. Fluorescent in situ hybridization (FISH) did not identify
ETV6-NTRK3 gene rearrangement or any karyotype anomalies.
Given the patient's prematurity and size, the decision was made to
defer adjuvant chemotherapy and a program of close surveillancender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography image of large right renal mass prior to surgical
resection. The mass is pushing the liver medially and to the patient's left side, with the
gallbladder and portal vein both visible to the left of midline.
Fig. 3. Computed tomography obtained for the presumed pulmonary metastasis ﬁrst
identiﬁed on chest X-ray in the right lung.
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Fourteen weeks after tumor resection (post-conceptual age 45
weeks), a right upper lobe lung nodule was noted on surveillance
chest x-ray. This was further evaluated with CT scan (Fig. 3), which
also demonstrated several lesions in the liver. There was no
radiographic evidence of local recurrence. One week later, the pa-
tient underwent a right thoracotomy and wedge resection of the
2 cm right upper lobe lung nodule (Fig. 4). Pathologywas consistent
with congenital mesoblastic nephroma, conﬁrming metastatic
disease.
Following resection of the lung nodule, and with evidence of
possible metastatic disease to the liver, adjuvant chemotherapy
was started. After completing a complete course of vincristine,
cyclophosphamide and dactomycin, the infant has demonstrated
complete response based on repeat imaging of the liver lesions.
3. Discussion
Although exceedingly rare, CMN is the most common renal tu-
mor diagnosed within the ﬁrst three months of life [6,7]. There is a
2:1 male predominance. The typical ﬁndings on presentation are a
palpable abdominal mass, hematuria, hypertension and poly-
hydramnios [8e10]. Prenatal diagnosis can be made withFig. 2. Specimen immediately following surgical resection. Normal kidney can be seen
on the inferior pole of the specimen (to the left), with the rest replaced by the large
tumor.ultrasound as in the present case [8,11]. Postnatal diagnosis can be
made with renal ultrasound and CT scan.
There are three types of histologic subtypes of CMN: classic
(24e58%), cellular (42e66%), and mixed-type (10%), with the
cellular and mixed-type known to have more aggressive charac-
teristics [6,7]. CMN is characterized by its spindle cells but the
cellular type is distinguished by larger nuclei, hypercellularity,
increased mitotic activity and the presence of necrosis [12]. The
cellular type is associated with a t(12;15)(p12;q25) translocation
resulting in a ETV6-NTRK3 fusion gene. This ﬁnding supports that
CMN is more closely related to infantile (congenital) ﬁbrosarcoma
(IF) rather than nephroblastoma (Wilms tumor) [13]; in fact some
authors refer to CMN as “infantile renal ﬁbrosarcoma” in order to
tie the two processes together [14].
CMN was ﬁrst distinguished as a separate entity from nephro-
blastoma by Bolande et al. in 1967 [7]. Radical nephrectomy alone
was considered adequate management. With the discovery of the
‘atypical’ or cellular variant by Joshi et al. the possibility of recurrent
and metastatic disease became apparent [2,3]. The risk for recur-
rent or metastatic disease is associated with intraoperative tumor
spillage, positive surgical margins, cellular type histology and open
biopsy [6,15]. Reports of metastatic disease are rare, however
known sites of distant metastasis include lung, liver, heart, and
brain [2,3,5,15e21].Fig. 4. Surgical specimen from right lung wedge resection. The pathology was
consistent with congenital mesoblastic nephroma, conﬁrming distant mestastasis.
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chemotherapy and radiation in the treatment of CMN. Early at-
tempts at treating CMN with chemotherapy regimens used in
nephroblastoma have not been successful [4,16]. Given the dis-
covery of the ETV6-NTRK3 fusion gene and close relation of CMN to
IF, advancements have been made in the use of ‘sarcoma’ based
chemotherapy regimens in patients with CMN with high risk for or
presence of recurrent or metastatic disease. Remission has been
seen with the use of regimens consisting of doxorubicin, vincris-
tine, and actinomycin/cyclophosphamide [4,5].
The identiﬁcation of patients at high risk for recurrent or met-
astatic disease remains a challenge. Overall survival with CMN has
been cited at 95%, however recurrent disease has been associated
with a mortality as high as 50% [4]. In the largest case series to date
from the Gesellschaft fur P€adiatrische Onkologie und H€amatologie
it was demonstrated that surgical resection alone was sufﬁcient
management in the majority of patients. The high risk subset for
recurrence and metastases included patients with stage III disease
who had the cellular subtype. In their series of 50 patients with
CMN, ﬁve patients had cellular subtype stage III disease; two pa-
tients did not receive adjuvant chemotherapy and had recurrence,
while three patients did receive adjuvant chemotherapy and did
not have recurrent disease [6].
This case is of interest for several reasons. First, it is the only
known published case of an infant born from twin gestation with
CMN. Second, at 29weeks this patient is one of the youngest infants
to be diagnosed with CMN, particularly with the cellular subtype,
which is more common in older infants. Further, the decision to not
give adjuvant chemotherapy following resection in this type of
scenario is controversial. It is impossible to say whether the patient
would have avoided metastases had he received adjuvant chemo-
therapy. Similarly, it is unknown what residual side effects may
have resulted from chemotherapy administration in such a young
infant. On the other hand, his good response to chemotherapy thus
far may in fact validate the initial avoidance of adjuvant chemo-
therapy until it is needed in the setting of conﬁrmed recurrent or
metastatic disease. This would in turn stress the importance of a
thorough surveillance program to identify recurrent or metastatic
disease at the earliest time point.
In conclusion, we report a case of a premature infant from a twin
gestation with stage III CMN who went on to develop distant me-
tastases. This case highlights the dilemma involved in deciding
whether to administer adjuvant chemotherapy to young infants at
higher risk for recurrence or metastases. At the present time such
decisions must be made on a case-by-case basis, as the rarity of this
condition precludes any type of prospective comparative analysis.
Reports such as this on individual cases or case series may in time
lead to the development of consensus-based guidelines in order to
guide future treatment.References
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